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Background: Scarcity of prospective medication non-adherence cost measurements for the
Australian population with no directly measured estimates makes determining the burden
medication non-adherence places on the Australian health care system difficult. This study
aims to indirectly estimate the national cost of medication non-adherence in Australia
comparing the cost prior to and following a community pharmacy-led intervention.
Methods: Retrospective observational study. A de-identified database of dispensing data
from 20,335 patients (n=11,257 on rosuvastatin, n=6,797 on irbesartan and n=2,281 on
desvenlafaxine) was analyzed and average adherence rate determined through calculation
of PDC. Included patients received a pharmacist-led medication adherence intervention and
had twelve months dispensing records; six months before and six months after the interven-
tion. The national cost estimate of medication non-adherence in hypertension, dyslipidemia
and depression pre- and post-intervention was determined through utilization of disease
prevalence and comorbidity, non-adherence rates and per patient disease-specific adherence-
related costs.
Results: The total national cost of medication non-adherence across three prevalent condi-
tions, hypertension, dyslipidemia and depression was $10.4 billion equating to $517 per
adult. Following enrollment in the pharmacist-led intervention medication non-adherence
costs per adult decreased $95 saving the Australian health care system and patients
$1.9 billion annually.
Conclusion: In the absence of a directly measured national cost of medication non-
adherence, this estimate demonstrates that pharmacists are ideally placed to improve patient
adherence and reduce financial burden placed on the health care system due to non-
adherence. Funding of medication adherence programs should be considered by policy and
decision makers to ease the current burden and improve patient health outcomes moving
forward.
Keywords: medication adherence, community pharmacy, big data, dispensing records,
health economics
Introduction
Appropriate use of medications remains sub-optimal despite their proven effective-
ness in preventing and managing chronic conditions.1 In an outpatient setting
medication non-adherence is one of the principal obstacles in successful pharma-
cotherapy, yet often fails to be clinically recognized.1 The high prevalence of
medication non-adherence is associated with increased morbidity and mortality,
disease progression and increased utilization of health care resources and
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accompanying expenditure.2,3 Nevertheless medication
non-adherence remains a neglected element of patient
therapeutic management.
Internationally the economic impact of medication
non-adherence has been examined at the macro-level in
a number of studies, independent reports and
gray literature findings. Heterogeneity exists in the
reported costs with limited information available to deter-
mine how these values were calculated. The 2013 IMS
“Avoidable Costs in US Healthcare” report stipulates that
annually US$105.4 billion or 3.9% of the nation’s health
care spending would be avoidable if medication non-
adherence were addressed.4 Furthermore, the “Advancing
the responsible use of medicines” report specifies that
medication non-adherence contributes 57% of the world’s
total avoidable cost due to suboptimal medicines use.5 The
quantification of cost avoidance and the research substan-
tiating these analyses implies that better use of medicines
can improve quality of life through reduced hospitaliza-
tions and improved health outcomes such as morbidity and
mortality. Figure 1 presents a timeline of the global pre-
dictive annual economic burden attributed to medication
non-adherence reported in the gray literature, highlighting
the tendency of medication non-adherence costs to
increase over time.
The microlevel economic examination of medication
non-adherence within single disease state studies supports
the determination that non-adherence is largely associated
with higher health care costs2,6–9 and solidifies big data
international projections.4,10 A recent systematic review
reported the annual adjusted disease-specific economic
cost of non-adherence to range from US$949 to
$44,190 per person. Costs associated with non-adherence
to cancer treatment ($114,101) were substantially higher
than costs associated with non-adherence to treatment for
cardiovascular disease ($16,124), mental health ($16,110)
or osteoporosis ($43,240).11 These micro costing studies,
however, are limited as they only report for a specific popu-
lation and fail to take into consideration recent changes in
disease prevalence. Additionally, the majority of the studies
are conducted in the United States (US) where health care is
generally more expensive, and the health insurance system
differs significantly between the US and Australia. Scarcity
of prospective medication non-adherence cost measure-
ments for the Australian population with no directly mea-
sured estimates reported makes the generalisability of these
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Figure 1 Timeline of macro-level medication non-adherence costs. Gray literature reports data demonstrating the increasing costs associated with medication non-
adherence over time.
Note: Costs in $ are expressed in US$.
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results limited in their pertinence to extrapolating national
cost estimates of medication non-adherence.
In Australia, inappropriate use of medicines costs the
Australian public hospital system AUD$1.2 billion per year
representing 2–3% of all hospital admissions, with this
figure rising to 20–30% of all admissions in the population
aged 65 years and over.12 It is estimated that 4.7% of the
total Australian health expenditure is avoidable due to sub-
optimal medicines use5 extrapolating to AUD$8 billion
annually.13 These costs, however, do not directly estimate
medication non-adherence and take into consideration
a number of confounding factors that contribute to inap-
propriate medication use. In addition to medication non-
adherence, these avoidable costs arise when patients fail to
receive the right medications at the right time or in the right
way, or receive them but fail to take them. Medication non-
adherence has been identified as an “opportunity cost” to
reclaim current health care spending wastage.4 Targeted
analysis is required to accurately estimate the associated
cost of medication non-adherence in Australia, which is
thought to be significantly underestimated.14–16
Improvements in health care in conjunction with pro-
longed life expectancy has resulted in a rise in the pre-
valence of chronic conditions ultimately increasing the
burden placed on health care systems and subsequently
leading to a higher number of prescription medications and
budgetary spending allocations to manage these
conditions.17 Most illnesses and deaths in Australia are
caused by chronic conditions with an estimated 1 in 2
Australians (50%) suffering from at least one chronic
condition.18 Cardiovascular disease and mental health con-
ditions are two of the most prevalent chronic conditions,
with 1 in 5 (18%) Australians experiencing one of these.18
Suboptimal adherence to commonly prescribed medica-
tions in cardiovascular disease and mental health contri-
bute significantly to disease progression and mortality,19–22
increasing the budget impact on the Australian health care
system. Increased availability of large prescription data
sets enhances the analysis and evaluation of patient med-
ication adherence, enabling a cost-effective approach to
estimate the economic impact of medication non-
adherence.23,24
With up to 30% of the prescriptions never being filled
and approximately 50% of the people with chronic condi-
tions stopping their medications within the first twelve
months,25 the negative financial implications of medica-
tion non-adherence are of paramount concern. Evidence
supports that community pharmacists are ideally situated
to deliver medication adherence interventions;26 however,
further examination is necessary to determine the broader
economic impact pharmacist medication adherence inter-
ventions have in cost savings to the Australian health care
system. In the absence of a directly measured national cost
of medication non-adherence, this study aims to indirectly
estimate the national cost of medication non-adherence in
Australia comparing the cost prior to and following
a community pharmacy-led intervention. Utilizing popula-
tion-based and pharmacy claims data, a transparent and
replicable model will be developed to determine the
national estimate of medication non-adherence in hyper-
tension, dyslipidemia and depression27 prior to and follow-
ing a community pharmacy-based intervention through
examining medication use of three molecules rosuvastatin,
irbesartan and desvenlafaxine.
Methods
Study design and data sources
A retrospective analysis of de-identified patient pharmacy
dispensing data from the GuildLink Pty Ltd database was
conducted. GuildLink Pty Ltd is a wholly owned subsidi-
ary of the Pharmacy Guild of Australia, which focuses on
providing software solutions to community pharmacies to
aid in the provision and documentation of pharmacy
services.
The MedScreen Compliance program was utilized to
identify patients receiving an educational-based interven-
tion to enhance medication adherence from community
pharmacies across Australia. This program is designed to
help ensure that quality use of medicine is achieved and
adherence to prescribed therapy is maintained or
improved. The service targets non-adherent patients when
a calculated medication possession ratio (MPR) is below
70%. The clinical service consists of 1) identifying
patient-specific barriers and facilitators to medication
adherence; 2) engaging patients in a brief pharmacist edu-
cational interaction regarding adherence and quality use of
medicines, this includes provision of either oral or written
communication to enhance patient understanding and
emphasize the importance of adherence; 3) goal setting
for patient treatment targets and 4) recording the interac-
tion and making patient-specific notes.28 Patients could
receive one or multiple interventions across time periods
depending on the calculated MPR, alerting the pharmacist
to invite the patient to the intervention if they remain
below the 70% adherence threshold.
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The unique patient identifier allowed patients enrolled
in the MedScreen Compliance intervention to be anon-
ymously identified and their medication adherence rates
tracked. One year dispensing history was analyzed for
each patient who completed the intervention; six months
prior to the adherence intervention and six months follow-
ing the intervention. Process indicators to validate the
fidelity of the intervention were not available.
Medication adherence
Descriptive outcomes included adherencemeasures in patients
with a dispensing history during the six months prior to the
MedScreen Compliance intervention (pre-intervention/base-
line), when the intervention was performed and six months
following the intervention (post-intervention). For this analy-
sis, adherence to three molecules rosuvastatin, irbesartan and/
or desvenlafaxine was determined using the proportion of days
covered (PDC). The three molecules modeled disease state
prevalence. PDC was defined as the total number of days
supplied with the medication during the six-month period
before and after the intervention divided by the total number
of days in the fixed period. Analysis was conducted per
trimesters, 6 months before and 6 months after the first phar-
macist intervention, calculating the average PDC (%) and
standard deviation (SD) for all patients in each period using
descriptive statistics.29 Adherence was defined as a PDC of
80% or greater, the most common threshold for adequate
adherence to chronic medications.30 The number of non-
adherent patients for each condition was determined by multi-
plying the rate of non-adherence pre- and post-intervention
with the Australian adult population with the disease. This
indicator was selected instead of MPR as it does not over-
estimate adherence, provides a conservative estimate and
accounts for overlapping days supply.31
Estimates of the Australian population and number of
patients with hypertension, dyslipidemia and depression
were collected from the Australian Bureau of
Statistics.18,32–35 The steps and sources of data used in
the cost estimation are depicted in Figure 2 adapted from
Nasseh et al27, data input values are presented in Table 1.
The prevalence rates of the conditions were multiplied by
the total Australian population to determine national
estimates.
Cost calculations
Monetary values attributed to medication non-adherence
for hypertension, dyslipidemia and depression were iden-
tified from the literature.11 All costs were converted to
Figure 2 Derivation of the cost of medication non-adherence.
Note: Stepwise approach in the methodology (adapted from Nasseh et al23)undertaken to estimate the national cost of medication non-adherence in Australia pre- and
post-community pharmacist-led intervention.
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Australian dollars (2018 values) using the Cochrane
Economics Methods Group - Evidence for Policy and
Practice Information and Coordinating - Centre Cost
Converter tool.36 The most conservative non-adherence
cost estimate (minimum reported value) was utilized to
extrapolate national expenditure attributed to non-
adherence across each disease, radical estimates repre-
sented the maximum reported value in the literature.
Comorbidity risk adjustment was undertaken to prevent
duplication of non-adherence costs across multiple condi-
tions. Within the non-adherent hypertension, dyslipidemia
and depression population estimations were made for the
number of patients with only 1 of the conditions and all
combinations of 2 or 3 of the comorbid conditions. The
national non-adherence cost estimate was further evaluated
in terms of the cost outcome indicators that contributed to
the total cost through application of the MACE
framework37 examining national hospital cost data,38 and
the Pharmaceutical Benefits Scheme expenditure data.39
Sensitivity analysis
A sensitivity analysis was conducted to quantify the
changes in estimated total cost of non-adherence when
varying adherence thresholds and cost inputs. As
varying evidence exists quantifying the range of med-
ication non-adherence rates, we conducted a sensitivity
analysis using various adherence thresholds. For this
sensitivity analysis in accordance with Meichenbaum
et al, thresholds of 0.30, 0.40, 0.50, 0.60 in addition to
pre-intervention and post-intervention thresholds iden-
tified in this study were analysed holding all other
inputs fixed.40 Additional analyses were conducted to
examine the effects of conservative versus radical cost
inputs to estimations at 30% and 50% non-adherence
rates.
Ethical considerations
Ethics approval was granted by the University of




The GuildLink Pty Ltd database comprised prescription dis-
pensing histories and intervention offerings for 2,530,562
million patients serviced through 3,318 pharmacies across
Australia, providing in excess of 22 million dispensing
records. A total of 20,335 patients (n=11,257 rosuvastatin,
Table 1 Derivation of cost process. Outlines data input values to determine the national cost estimate of medication non-adherence
in Australia
Derivation of cost process Reported findings
Australian adult population (2018)18,35 20,160,000
Hypertension33 Dyslipidemia34 Depression33
Prevalence rates of conditions 34% 32.8% 17.5%
Prevalence rates of conditions (number of patients) 6,854,400 6,612,480 3,528,000
Average estimated PDC 6 month’s pre- and post-intervention Pre 45.5% Pre 45.6% Pre 52%
Post 37.1% Post 37.6% Post 40.5%
National prevalence of medication non-adherence Pre 3,118,752 Pre 3,015,290 Pre 1,834,560
Post 2,542,982 Post 2,486,292 Post 1,428,840
Disease-specific non-adherence cost ($AUD)11,36,41 Min $2,386 Min $8,125 Min $3,812
Max $13,493 Max $14,631 Max $24,717
Conservative national estimate ($AUD) Pre $1,994,279,728 Pre $6,565,793,975 Pre $1,874,215,848
Post $1,626,104,753 Post $5,413,900,830 Post $1,459,725,805
Radical national estimate ($AUD) Pre $11,277,793,957 Pre $11,823,277,741 Pre $12,152,411,631
Post $9,195,738,241 Post $9,749,019,451 Post $9,464,859,059
Abbreviations: PDC, proportion of days covered; Pre, pre-adherence intervention; Post, post-adherence intervention.
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n=6,797 irbesartan and n=2,281 desvenlafaxine) from 1,805
pharmacies across Australia, were included in the analysis.
The average number of patients per pharmacy was 11.27
(SD: 3.77) compared to 8.59 (SD: 5.14) across the entire
database as patients visited multiple pharmacies.
The average age was highest in patients taking irbe-
sartan 67 (SD: 12.42), followed by 65 (SD: 11.76) in
rosuvastatin and 50 (SD: 15.70) for desvenlafaxine.
Female patients represented a higher proportion of the
population with the distribution of gender following
a similar trend across molecules. For patients taking
rosuvastatin 56% were female and 44% male, irbesartan
61% female and 39% male and desvenlafaxine 70%
female and 30% male.
Medication adherence
The MedScreen Compliance intervention increased
average PDC from 52.3% at baseline (SD: 31.4) by
9.3% to 61.6% (SD: 31.7), while from the intervention
time point average PDC increased from 49.3% (SD:
30) by 12% to 61.6%(SD: 31.7). Desvenlafaxine dis-
played the overall lowest average PDC of the three
molecules at baseline (48%, SD: 30.3) and post-
intervention (59.5%, SD: 30.6) however simultaneously
demonstrated the greatest proportional increase in
adherence over time following the intervention (PDC
11.5%, SD: 29.3). Similar results were established
between rosuvastatin and irbesartan with PDC over
time increasing on average 8% (SD: 30.8) and 8.4%
(SD: 31) respectively. Across all three molecules there
was a trend for medication adherence to decrease from
baseline to the intervention, peak in the trimester fol-
lowing the intervention before slowly decreasing and
plateauing (rosuvastatin PDC 62.4% (SD: 31.7),
irbesartan PDC 62.9% (SD: 32) and desvenlafaxine
PDC 59.5% (SD: 30.6)).
Cost estimation
The total national cost of medication non-adherence
across three prevalent disease states in 2018 prior to
a community pharmacy-led intervention was
$10.4 billion equating to approximately $517 per adult
in Australia. Following enrollment in the MedScreen
Compliance intervention medication non-adherence
costs per adult decreased $95 saving the Australian
health care system and patients $1.9 billion annually.
Figure 3 depicts the national cost range of medication
non-adherence pre and post-adherence intervention.
Significant reductions in cost expenditure were demon-
strated across all three conditions with depression exhi-
biting the greatest saving as a proportion of the original
expenditure (22%). Dyslipidaemia demonstrated the lar-
gest dollar figure saving ($1.1 billion), however, was the
smallest as a proportion of the original expenditure
(17.5%). The same trends were demonstrated when
applying the conservative and radical approach.
With over 85% of the non-adherence costs attributed
to medical-related expenses, application of the MACE
framework37 to the conservative extrapolated costs facil-
itates the estimation of the proportion of costs attributed
to various cost outcome indicators. Of the $8.4 billion
annual non-adherence cost post intervention, $2.1 billion
arose from the outpatient setting, $1.9 billion from
inpatient-related expenses, $1.8 billion on prescription
medications and $1.6 billion were attributed to medical
related costs such as general practitioner visits. If no
adherence intervention is received the baseline non-
adherence cost of $10 billion can be broken down into






















Figure 3 National cost range of medication non-adherence pre and post-adherence intervention. Bars represent the conservative and radical cost associated with
medication non-adherence across three chronic conditions hypertension, dyslipidemia and depression. Chart comparison demonstrates Australian national cost range pre
and post-community pharmacist-led medication adherence intervention.
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$2.6 billion outpatient costs, $2.3 billion inpatient costs,
$2.2 billion prescription medication and $1.9 billion
medical expenses.
Sensitivity analysis
Similar results were seen when cost estimation was performed
using different adherence thresholds. Non-adherence costs
decreased across all three molecules as adherence thresholds
increased. Application of the conservative estimation across
30% and 50% non-adherence thresholds resulted in a total cost
range varying between $6.7 billion ($333 per adult) to
$11.1 billion ($555 per adult) annually. When applying the
radical costing assumption to estimate disease-specific costs,
the estimated national cost of medication non-adherence rose
substantially ranging from $22.2 billion ($1,102 per adult) to
$37 billion ($1,837 per adult).
Discussion
The Australian national cost estimate of medication non-
adherence across three highly prevalent chronic conditions
prior to a community pharmacy-led intervention was
$10.4 billion or $517 per adult. Aitken et al5 approximated
that 4.7% of the total Australian health expenditure is
avoidable due to suboptimal medicines use extrapolating
to $8 billion annually.13 This estimate did not directly
measure medication non-adherence but rather examined
inappropriate medication use. The extrapolated estimate
although 25% higher than the value predicted by Aitken
et al provides a more accurate evaluation utilizing pharmacy
claims data, literature values and current disease prevalence
to determine the cost of medication non-adherence in
Australia. This cost reduced to $8.4 billion or $421 per
adult following the MedScreen Compliance intervention.
Sustainability of the Australian health care system pre-
sents a major challenge and concern, with current levels of
funding set to create significant financial burden for govern-
ments in the future.41 The emergence of new health chal-
lenges, the aging population and the increase in risk factors
for chronic conditions in combination with the expectation
of the Australian population to provide higher standards of
care and subsidization fuel this situation. While Australia
has a good health system by international standards, it is
estimated that spending on health care by government as
a percentage of gross domestic product will nearly double
by 2050.42 There are fears that the current level of funding
is not sustainable and new models need to be considered.41
Subsidization of the Pharmaceutical Benefits Scheme
represents 30% of the funds administered by the
Department of Health and the Medical Benefits Scheme
52%.43 Funding of strategies including pharmacist-led ser-
vices to improve medication adherence, removes wastage
and inefficient usage of the current system, resulting in
more sustainable, cost-effective resource allocation.
Interventions to improve medication adherence have
consistently demonstrated an improvement in health care
outcomes and a reduction in total health care costs.44
A recent systematic review conducted by Milosavljevic
et al45 found that overwhelmingly community pharmacist-
led intervention improved patients’ adherence contributing
to better blood pressure control, cholesterol management,
chronic obstructive pulmonary disease and asthma control.
However, studies in the review did not report statistically
significant effects of interventions on diabetes or depres-
sion control,45 challenging the results found from
improvements demonstrated with the MedScreen compli-
ance intervention in depression. Data from the GuildLink
Pty Ltd database supports the improvement of patient
adherence rates in hypertension, dyslipidemia and depres-
sion measured through calculation of PDC increasing on
average 9.3% from baseline and 12% from intervention
date. Accompanying cost extrapolation data further har-
nesses these findings with a $1.9 billion annual cost saving
attributable to the MedScreen Compliance intervention
across the three molecules. While the intervention demon-
strates improvements in medication adherence rates in the
six months ensuing, sustaining improvements long term
requires further investigation and represents an obstacle in
reducing future preventable health care expenditure.
The low number of studies directly comparing adherence
interventions thwarts the determination of the most effective
intervention. A recent network meta-analysis likening the
effect of all interventions in one single model ranks interven-
tions containing an economic component followed by tech-
nical component with the best results. Educational or
attitudinal components were ranked next, with standard care
always considered the worst option.46 The GuildLink adher-
ence intervention relies on educational components to
enhance medication adherence. Moving forward incorporat-
ing attitudinal and technical components into this interven-
tion would improve results. Evidence suggests that only 20%
of the national health interventions produce sufficient savings
to be at or near budget neutrality.47 A balance between
intervention costs and achievable savings attributable to the
intervention needs to be obtained. Financial incentives or
rewards are not necessarily a viable long-term solution for
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a national health strategy. While exhibiting some success in
improving processes in primary care, limited evidence of
improved health outcomes or cost savings exists with inter-
ventions containing economic motivation, often eroding
the potential economic gain.48–50 Medication adherence
intervention programs represent an opportunistic national
policy initiative to increase utilization of prescription
medication to reduce the preventable burden currently
placed on the Australian health care system.
Pharmacists are ideally placed to implement, modify
and sustain clearly defined adherence-enhancing inter-
ventions across a dynamic population. This way they
can minimize negative therapeutic outcomes due to non-
adherence, while increasing prescription volumes.51
The strategy developed to quantify the economic
impact of medication non-adherence in Australia was con-
ceptual. To date, there has been no specific estimate of the
cost medication non-adherence poses to the Australian
population. This study improves upon previous interna-
tional estimates, despite its limitations. Actual medical
condition prevalence estimates were applied from latest
available population statistics.33,34 A national representa-
tive sample of non-adherent Australian adults were uti-
lized to determine average medication adherence rates
from prescription dispensing histories. Disease-specific
per person cost of non-adherence was derived from the
literature employing a “conservative” and “radical”
approach. This analysis attempted to make estimates
within a conceptual model that can be further tested and
refined. Nonetheless, estimates from this study relied on
data in the literature and on tertiary health statistics sum-
maries. Moving forward the strategy should be tested in
a real-life setting incorporating the determination of actual
costs associated with this health problem. Prospective
measurement of resource use in patients who receive the
MedScreen Compliance intervention versus those who do
not would address this. Furthermore, the current cost esti-
mates only take into consideration three chronic condi-
tions: hypertension, dyslipidemia and depression. For
a more holistic outlook on the burden medication non-
adherence places on the Australian health care system,
additional conditions should be examined. Additionally,
it would be beneficial to examine the offset of costs
associated with delivering the service compared to cost-
saving potential. Currently, costs associated with deliver-
ing the service have not been considered. Despite these
limitations, analysis of the economic impact of medication
non-adherence across three highly prevalent conditions,
utilizing real-life data demonstrated the positive impact
pharmacist-led intervention can provide. Even when
a conservative approach is employed.
Conclusion
Medication non-adherence across hypertension, dyslipide-
mia and depression costs $10.4 billion annually, signifi-
cantly contributing to avoidable health care costs in
Australia. Community pharmacist-led medication adher-
ence interventions have been demonstrated to improve
adherence rates by 9.3% over a 12-month period, reducing
the burden incurred by non-adherence by $1.9 billion.
Given these findings, policy and decision makers should
consider funding medication adherence programs to
improve patient health outcomes and save money.
Actively encouraging medication adherence through phar-
macist-led intervention should be a top priority.
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